The subject of the call with the pharma CEO was not new territory for either one of us: the non-executive chairman of his company’s board wanted to micromanage and get deeply involved when he had the time or interest, and would go missing in action when the heavy or unpleasant work (like letting the founder know he was off the board of directors) came around.… Read the rest